PET Imaging Evaluation of [11C]SY08

Recruiting Early Phase 1 Interventional Study
Parkinson's Disease Multiple System Atrophy Dementia With Lewy Bodies Healthy Controls
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
50 – 80
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Basic Science
Participants needed
40 (estimated)
Sponsor
Massachusetts General Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DL…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * General Inclusion criteria, all subjects must: 1. Age 50-80 2. Be able to provide written informed consent or assent 3. Be able to read, speak and understand English (The investigators do not have the resources necessary to properly study non-English speaking patients i…
Contacts

Changning Wang, PhD

6177243983

cwang15@mgh.harvard.edu

CONTACT